Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adagio Medical Holdings, Inc.ADGM · Entity 7926 | Director | June 16, 2026 | August 12, 2026 |
| Cerevel Therapeutics Holdings, Inc.CERE · Entity 15182 | Chief Business Officer | January 25, 2021 | January 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adagio Medical Holdings, Inc.
Report date June 16, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2036-06-16 | Direct | 100,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 100,000 · Balance 100,000 F1: Annual stock option granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest in equal monthly installments over a one-year period, whereby 1/12th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual stock option granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest in equal monthly installments over a one-year period, whereby 1/12th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026.
Cerevel Therapeutics Holdings, Inc.
Report date January 25, 2021 · Filed January 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,450 |
Reported balance
After 2021-01-26 transaction · row 1
1 source rowRow 1 · 2021-01-26 · Exercise / conversion · Acquired 38,450 · Balance 38,450 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2029-06-25 | Direct | 426,913 |
Reported balance
After 2021-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-26 · Exercise / conversion · Disposed 38,450 · Balance 426,913 F1: 25% of the shares subject to this option vested and became exercisable on July 15, 2020, with remainder vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option vested and became exercisable on July 15, 2020, with remainder vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Aug 12, 2026 17:36 UTC | Adagio Medical Holdings, Inc. ADGM · Entity 7926 | GrantNon-qualified stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001830911-26-000002 · form4-08122026_050812.xml · derivative · entry 1 MISHAN ORLY · CIK 0001830911 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-06-16 F1 · security: Annual stock option granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest in equal monthly installments over a one-year period, whereby 1/12th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026. F1 · derivative.exercise_date: Annual stock option granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest in equal monthly installments over a one-year period, whereby 1/12th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 22:58 UTC | Adagio Medical Holdings, Inc. ADGM · Entity 7926 | GrantNon-qualified stock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001415889-25-008803 · form4-03212025_100335.xml · derivative · entry 1 MISHAN ORLY · CIK 0001830911 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-07-31 F1 · security: Stock option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Option will vest over a three-year period, whereby 1/36th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of July 31, 2024. F1 · derivative.exercise_date: Stock option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Option will vest over a three-year period, whereby 1/36th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of July 31, 2024. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:35 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 38,450 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000899243-21-003665 · doc4.xml · derivative · entry 2 MISHAN ORLY · CIK 0001830911 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,913 Underlying: Common Stock · 38,450 shares Expires 2029-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on July 15, 2020, with remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:35 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 38,450 | $3.50 | $134,575.00 |
DisclosureSEC source: 0000899243-21-003665 · doc4.xml · nonDerivative · entry 1 MISHAN ORLY · CIK 0001830911 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.